Bolt Biotherapeutics (BOLT) announced that the target of their worldwide co-development collaboration with Toray Industries is Caprin-1, a cancer target discovered by Toray. The collaborators are developing a Boltbody Immune-Stimulating Antibody Conjugate targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing joint development and license agreement, Toray supplies its proprietary antibodies targeting Caprin-1, such as the antibody TRK-950, and Bolt contributes proprietary linker-payloads from its Boltbody ISAC platform technology. Bolt plans to co-develop and jointly commercialize the resulting ISAC product candidate with Toray.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BOLT:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue